These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35097101)

  • 1. Accelerated Infliximab Induction for Severe Lower Gastrointestinal Bleeding in a Young Patient with Crohn's Disease: A Case Report.
    Zeng J; Shen F; Fan JG; Ge WS
    World J Clin Cases; 2022 Jan; 10(2):733-740. PubMed ID: 35097101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [X-linked inhibitor of apoptosis deficiency manifested as Crohn's disease: a case report and literature review].
    Xu LJ; Luo YY; Yu JD; Lou JG; Fang YH; Chen J
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):43-47. PubMed ID: 29342997
    [No Abstract]   [Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
    Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
    Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.
    Kaymak T; Moriconi F; Niess JH; Beglinger C; Hruz P
    Inflamm Intest Dis; 2018 Mar; 2(3):171-179. PubMed ID: 30018967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
    Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
    Ohem J; Hradsky O; Zarubova K; Copova I; Bukovska P; Prusa R; Malickova K; Bronsky J
    Dig Dis; 2018; 36(1):40-48. PubMed ID: 28817809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
    Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
    Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of infliximab in the treatment of pediatirc Crohn's disease].
    Xu X; Xiao Y; Yu Y; Li J; Huang YQ; Cao W; Hu H; Zhang T; Xu CD; Wang XQ
    Zhonghua Er Ke Za Zhi; 2021 Jul; 59(7):557-562. PubMed ID: 34405637
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel role of the splenic volume in Crohn's disease: evaluating the efficacy of infliximab.
    Shi X; Wang JH; Rao SX; Liu TT; Wu H
    Front Pharmacol; 2023; 14():1246657. PubMed ID: 37663264
    [No Abstract]   [Full Text] [Related]  

  • 15. Endoscopic monitoring of infliximab therapy in Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
    Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study of efficiacy of infliximab treatment for Crohn's disease.].
    Zheng JJ; Wang YM; Zhu F; Gu W; Xing YC; Zhou CL; Shen BW
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):922-5. PubMed ID: 20079322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage.
    Papi C; Gili L; Tarquini M; Antonelli G; Capurso L
    J Clin Gastroenterol; 2003 Mar; 36(3):238-41. PubMed ID: 12590236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.